The 1D11.16.8 monoclonal antibody reacts with mouse, human, rat, monkey, hamster, canine and bovine TGF-β (transforming growth factor beta) isoforms 1, 2 and 3.The 1D11.16.8 monoclonal antibody is a neutralizing antibody.

The 1D11.16.8 monoclonal antibody reacts with mouse, human, rat, monkey, hamster, canine and bovine TGF-β (transforming growth factor beta) isoforms 1, 2 and 3.The 1D11.16.8 monoclonal antibody is a neutralizing antibody.

The 1D11.16.8 monoclonal antibody reacts with mouse, human, rat, monkey, hamster, canine and bovine TGF-β (transforming growth factor beta) isoforms 1, 2 and 3.The 1D11.16.8 monoclonal antibody is a neutralizing antibody.

Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.

Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.

Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD.

Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD.

Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD.

Anti-ICOS/CD278 (MEDI-570) is a Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278) with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat non-Hodgkin lymphomas. MW: 146.82 KD.

Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD.

Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD.

Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD.

Anti-IFNg (AMG 811) is a human monoclonal antibody (IgG1 isotype) that selectively targets human IFNgamma 7. It has potential to treat systemic lupus erythematosus (SLE). MW: 144.36 KD.

Anti-IFNg (AMG 811) is a human monoclonal antibody (IgG1 isotype) that selectively targets human IFNgamma 7. It has potential to treat systemic lupus erythematosus (SLE). MW: 144.36 KD.

Anti-IFNg (AMG 811) is a human monoclonal antibody (IgG1 isotype) that selectively targets human IFNgamma 7. It has potential to treat systemic lupus erythematosus (SLE). MW: 144.36 KD.

Anti-IGF2 (DX-2647) is a human monoclonal antibody against insulin-like growth factor-II (IGF-II) with anti-tumor  and anti-proliferative activities. MW: 145.78 KD.

Anti-IGF2 (DX-2647) is a human monoclonal antibody against insulin-like growth factor-II (IGF-II) with anti-tumor  and anti-proliferative activities. MW: 145.78 KD.

Anti-IGF2 (DX-2647) is a human monoclonal antibody against insulin-like growth factor-II (IGF-II) with anti-tumor  and anti-proliferative activities. MW: 145.78 KD.

Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD.

Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD.

Anti-IL-10 (BT-063) is a human monoclonal antibody directed against the human interleukin 10 (IL-10). It has the potential to be used in the treatment of systemic lupus erythematosus (SLE). MW: 145.74 KD.

Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.

Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.

Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.

Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD.

Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD.

Anti-IL-13 (GSK 679586) is a humanized monoclonal IgG1 antibody against interleukin-13 (IL-13). It has the potential to treat chronic spontaneous urticaria. MW: 148.38 KD.

Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD.

Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD.

Anti-IL-13 (H2L6) is a humanized antibody against interleukin-13 (IL-13). MW: 146.16 KD.

Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD.

Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD.

Anti-IL-13 (IMA-026) is a humanized IgG1 antibody targated against interleukin 13 (IL-13) with the potential to treat chronic spontaneous urticaria. MW: 146.88 KD.

Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD.

Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD.

Anti-IL-13 (M1295) is a humanized antibody against interleukin-13 (IL-13). MW: 145.8 KD.

Anti-IL-13Ra1 / CD213a1 is a monoclonal antibody targeting IL13RA1. It can be used in research of therapeutic antibody for biological drug discovery. MW :145.5 KD.

Anti-IL-13Ra1 / CD213a1 is a monoclonal antibody targeting IL13RA1. It can be used in research of therapeutic antibody for biological drug discovery. MW :145.5 KD.

Anti-IL-13Ra1 / CD213a1 is a monoclonal antibody targeting IL13RA1. It can be used in research of therapeutic antibody for biological drug discovery. MW :145.5 KD.

Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.

Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.

Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD.

Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD.

Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD.

Anti-IL-15 (DISC0280) is a human monoclonal antibody targated againts Interleukin-15 (IL-15). MW: 145.62 KD.

Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 KD.

Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 KD.

Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 KD.

Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD.

Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD.